Viking Therapeutics Prepares for Key Phase III Results Amid Competitive Pressures
PILLAR DIAGNOSTIC // WEEK 16
“Despite on-track Phase III timing and bullish consensus on VK2735’s data readout, intensifying competition in the dual GIPR/GLP-1 space and a lack of buying momentum suggest shares may trade sideways until efficacy or M&A catalysts emerge.”
Proposed action
Maintain a neutral stance; avoid initiating new positions ahead of key data catalysts.
THE MECHANICS
Tape & flow
—
THE MACHINE
Operational momentum
Oral VK2735 is on track to enter Phase III in Q3 2026, with full obesity Phase III results expected next year, which is anticipated to resolve existing cost-of-goods and late-to-market concerns and unlock material value post-data.
THE MAP
Structure & constraints
Viking Therapeutics is developing an oral and a subcutaneous dual GIPR/GLP-1 agonist for obesity, indicating smaller biotechs are intensifying competitive pressure on established players.
THE MOOD
Consensus & positioning
Investors are optimistic about Viking’s eye-catching trial results and view it as a potential takeover candidate, buoyed by strong investor enthusiasm in 2025, even as they brace for widening full-year losses and steep EPS decline.